STEWART Washer has resigned from the position of chief executive officer of biopharmaceutical company, Phylogica. The company says it has launched an international search for a new CEO to take it from drug discovery into a next phase of drug development. As part of the new strategy, international drug development expert Doug Wilson was appointed to the board. Dr Wilson was a senior vice president for medicine and regulatory affairs for Boehringer Ingelheim in the US and has also overseen multiple drug registration in Europe.